Novartis reported Phase 3 data showing its ganaplacide–lumefantrine combination (GanLum) met the trial’s noninferiority endpoint and achieved cure rates at or above WHO targets. The company said GanLum demonstrated efficacy against drug-resistant Plasmodium strains and blocked transmission in trial cohorts across sub-Saharan Africa. Novartis intends to seek regulatory approvals based on the Phase 3 outcome and emphasized the public-health implications amid rising artemisinin resistance. Trial size, sites, and primary endpoint data were disclosed in company releases and conference summaries.